CN113694042B - Method for preparing cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning and application - Google Patents

Method for preparing cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning and application Download PDF

Info

Publication number
CN113694042B
CN113694042B CN202110936479.XA CN202110936479A CN113694042B CN 113694042 B CN113694042 B CN 113694042B CN 202110936479 A CN202110936479 A CN 202110936479A CN 113694042 B CN113694042 B CN 113694042B
Authority
CN
China
Prior art keywords
cyclodextrin
flavonoid
antibacterial film
inclusion compound
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110936479.XA
Other languages
Chinese (zh)
Other versions
CN113694042A (en
Inventor
宋梦
常超康
喻国敏
秦琦
岳秀琳
曹凤仪
焦书燕
焦明立
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongyuan University of Technology
Original Assignee
Zhongyuan University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongyuan University of Technology filed Critical Zhongyuan University of Technology
Priority to CN202110936479.XA priority Critical patent/CN113694042B/en
Publication of CN113694042A publication Critical patent/CN113694042A/en
Application granted granted Critical
Publication of CN113694042B publication Critical patent/CN113694042B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
    • D01D5/00—Formation of filaments, threads, or the like
    • D01D5/0007—Electro-spinning
    • D01D5/0015—Electro-spinning characterised by the initial state of the material
    • D01D5/0053—Electro-spinning characterised by the initial state of the material the material being a low molecular weight compound or an oligomer, and the fibres being formed by self-assembly
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F1/00—General methods for the manufacture of artificial filaments or the like
    • D01F1/02—Addition of substances to the spinning solution or to the melt
    • D01F1/10—Other agents for modifying properties
    • D01F1/103—Agents inhibiting growth of microorganisms
    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
    • D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
    • D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
    • D04H1/728—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Textile Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Manufacturing & Machinery (AREA)
  • Nutrition Science (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a method for preparing a cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning and application thereof, wherein the method comprises the following steps: slowly adding cyclodextrin into a certain volume of solvent under stirring, stirring at room temperature until the cyclodextrin is completely dissolved, slowly adding flavonoid compound into the certain volume of solvent under stirring, stirring at a certain temperature until the flavonoid compound is completely dissolved, slowly adding the flavonoid compound solution into the cyclodextrin solution under stirring, stirring the mixed solution at the certain temperature for 8-12 hours, performing rotary evaporation, filtering to remove the non-included flavonoid compound, taking the filtrate, freeze-drying to obtain an inclusion compound, and dissolving the inclusion compound in a small amount of deionized water to obtain a high-concentration spinning solution; and (3) carrying out electrostatic spinning by adopting the spinning solution to obtain a nanofiber antibacterial film, and finally carrying out vacuum drying to obtain the nanofiber antibacterial film. The method has the advantages of fewer steps, simplicity in operation, time saving, easiness in obtaining raw materials, capability of obtaining the nano-scale antibacterial film and suitability for large-scale production.

Description

Method for preparing cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning and application
Technical Field
The invention belongs to the field of preparation of electrostatic spinning nanofiber membranes, and particularly relates to a method for preparing a cyclodextrin flavonoid inclusion compound nano antibacterial membrane by polymer-free electrostatic spinning and application of the cyclodextrin flavonoid inclusion compound nano antibacterial membrane.
Background
In recent years, electrostatic spinning technology is increasingly applied to the field of medicine, drugs can be distributed in nano fibers in an amorphous form through electrostatic spinning, the water solubility of the drugs is greatly increased to improve the bioavailability, and meanwhile, pharmacological properties of the drugs are not affected, so that the research on the application of electrostatic spinning to a drug delivery system has great application potential and good prospects. For example, zhui minn, sun dawn bamboo, etc. (CN 102851789A) a preparation method of electrospun fiber containing β -cyclodextrin inclusion compound prepared β -cyclodextrin inclusion compound, added polymer to form spinning solution, and electrospun to prepare nanofiber; shenwang, sun Wei et al (CN 105568552A), a quercetin clathrate electrospinning nanomembrane, its preparation method and application use a solution method to prepare quercetin beta-cyclodextrin clathrate and use zein as polymer to prepare spinning solution for electrospinning to obtain the nanomembrane; neihua, shuliju (CN 107287766A), a method for preparing polyacrylonitrile/curcumin nano-fiber mat by electrostatic spinning, directly prepares spinning solution added with polymer and carries out electrospinning to obtain the nano-mat. However, most of the research spinning solutions need to add polymers, and polymer-free electrostatic spinning can be performed without considering the types of polymers and the possible influence of the polymers, so that the operation steps are fewer, the operation is simpler and quicker, the materials are saved, and the cost is reduced.
Polymer-free electrospinning refers to a process in which a spinning solution without added polymer is jet-drawn into fibers, which can be prepared into nano-sized fibers. Compared with the traditional spinning method, the polymer-free electrostatic spinning nanofiber does not need to be added with a polymer, the equipment is simple, the operation is easy, the prepared nanofiber film has a mild drug loading mode, the drug activity cannot be damaged, and the drug is mostly distributed in the carrier in an amorphous form, so that the slow release of the drug is facilitated, and the bioavailability is effectively improved.
The flavonoid compound is a natural micromolecular compound, and modern pharmacological research shows that the flavonoid compound has wide pharmacological activities, including oxidation resistance, antibiosis, anti-inflammation, reduction of vascular fragility, inhibition of tumor cells and the like. However, most of the flavonoid compounds are crystalline solids, are poor in water solubility and easy to degrade, phenolic hydroxyl groups in the structure are easy to oxidize, and the bioavailability is extremely low, so that the clinical application of the flavonoid compounds is limited. The nano-fiber antibacterial film is prepared by cyclodextrin inclusion and electrostatic spinning, so that the water solubility of the flavonoid compound can be greatly improved, the bioavailability is increased, the toxic and side effects can be reduced, and the safety of medication can be improved. The single drug film has the characteristic of quick dissolution, and can be used for administration modes such as oral administration, implantation, injection and the like. The composite material is compounded with other spinning films, is used for wound dressing, and has the advantages of drug sustained release, air permeability and the like.
Disclosure of Invention
The invention aims to solve the technical problem of providing a method for preparing a cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning, which is simple, rapid, easy to operate, high-efficiency and low in cost, is suitable for batch production, and provides reference for novel transdermal drug delivery or skin wound dressing.
In order to solve the technical problems, the invention adopts the following technical scheme:
a method for preparing a cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning comprises the following steps:
(1) Preparing the cyclodextrin flavonoid inclusion compound: the preparation method comprises the steps of preparing a solution method, slowly adding cyclodextrin into deionized water under stirring, stirring at room temperature until the cyclodextrin is completely dissolved to obtain a cyclodextrin solution, slowly adding a flavonoid compound into absolute ethyl alcohol under stirring, stirring at 25 to 40 ℃ until the flavonoid compound is completely dissolved to obtain a flavonoid compound solution, slowly adding the flavonoid compound solution into the cyclodextrin solution under stirring, stirring the mixed solution at 55 to 65 ℃ for 8 to 12 hours, performing rotary evaporation, filtering to remove the non-included flavonoid compound, and freeze-drying the filtrate to obtain a cyclodextrin flavonoid inclusion compound;
(2) Preparing a spinning solution: dissolving the cyclodextrin flavonoid inclusion compound obtained in the step (1) in deionized water to obtain a high-concentration spinning solution;
(3) And (3) performing electrostatic spinning on the spinning solution obtained in the step (2) to obtain a nanofiber antibacterial film, and finally performing vacuum drying to obtain the nanofiber antibacterial film.
Further, the cyclodextrin flavonoid inclusion compound prepared in the step (1) can be prepared by a grinding method, which comprises the following steps: adding deionized water into cyclodextrin, stirring to obtain paste, adding flavonoids, grinding, adding small amount of deionized water, filtering to remove non-included flavonoids, and freeze drying the filtrate.
Further, in the step (1), the ratio of the cyclodextrin to the flavonoid compound is 1.
Further, no polymer is added in the preparation of the spinning solution in the step (2).
Further, the concentration of the high-concentration spinning solution in the step (2) is 160-200% (w/v).
In the step (3), the specification of an injector used for electrostatic spinning is 5mL, the specification of a needle is 22G-19G, the voltage is 15kV-18kV, an aluminum foil is used for grounded receiving of a receiving screen, the distance between the needle and the receiving screen is 10-18cm, the jet flow rate in the electrostatic spinning process is 0.3-1.0 mL/h, and the ambient humidity is 25% -50%.
The nanometer antibacterial film of the cyclodextrin flavonoid inclusion compound is prepared by the method.
The invention relates to application of a cyclodextrin flavonoid inclusion compound nano antibacterial film in the antibacterial field.
The method is simple, rapid and efficient, the raw materials are easy to obtain, and the nanofiber antibacterial film can be obtained.
Has the advantages that: 1. the method has simple and quick operation, saves time, can obtain the nanofiber antibacterial film, and is suitable for large-scale production; 2. the raw materials used in the invention are cheap and easily available, and have application potential in the field of medicine. 3. The nanofiber antibacterial film prepared by the invention can be applied to transdermal drug delivery systems such as oral administration, implantation and injection or skin wound local dressings, and has wide application in the field of medicines. 4. When the nanofiber antibacterial film prepared by the invention is used in a transdermal drug delivery system, the effect of instant dissolution can be achieved, and the bioavailability is effectively improved; the composite material is compounded with other electrospun films (such as polylactic acid, gelatin, chitosan and the like) to form a double-layer or multi-layer dressing, so that the bacterial infection at the wound can be effectively avoided, and the wound healing is facilitated.
Drawings
Fig. 1 is an infrared spectrum of the 2-hydroxypropyl- β -cyclodextrin curcumin clathrate prepared in example 2;
fig. 2 is an X-ray diffraction pattern of the 2-hydroxypropyl- β -cyclodextrin curcumin inclusion complex prepared in example 2;
fig. 3 is a differential scanning calorimetry plot of the 2-hydroxypropyl- β -cyclodextrin curcumin inclusion prepared in example 2;
fig. 4 is an electrospun film (a is the 2-hydroxypropyl- β -cyclodextrin curcumin inclusion electrospun film prepared in example 2, b is the 2-hydroxypropyl- β -cyclodextrin curcumin inclusion electrospun film prepared in comparative example 1, c is the 2-hydroxypropyl- β -cyclodextrin electrospun film);
FIG. 5 is a photograph of a sample before culturing Staphylococcus aureus (a-example 2, b-comparative example 1);
FIG. 6 is a photograph of a sample after culturing Staphylococcus aureus (a-example 2, b-comparative example 1);
FIG. 7 is a photograph of the dissolution of the electrospun film in water (left is the electrospun film of comparative example 1 and right is the electrospun film of example 2).
Detailed Description
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Further, it should be understood that various changes or modifications of the present invention may be made by those skilled in the art after reading the teaching of the present invention, and such equivalents may fall within the scope of the present invention as defined in the appended claims.
Example 1
A method for preparing cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning comprises the following steps:
(1) Preparing a cyclodextrin curcumin clathrate: slowly adding 2-hydroxypropyl-beta-cyclodextrin into deionized water with a certain volume under stirring, stirring at room temperature until the 2-hydroxypropyl-beta-cyclodextrin is completely dissolved, slowly adding curcumin with the amount of 1/2 of the cyclodextrin substance into anhydrous ethanol with a certain volume under stirring, stirring at 30 ℃ until the curcumin is completely dissolved, slowly adding curcumin solution into cyclodextrin solution under stirring, stirring the mixed solution at 60 ℃ for 8 hours, performing rotary evaporation, filtering, taking filtrate, and freeze-drying to obtain an inclusion compound;
(2) Preparing a spinning solution: dissolving the inclusion compound in the step (1) in 5mL of deionized water, standing for 2h, and preparing spinning solution with the inclusion compound concentration of 180% (w/v);
(3) Using a 5 mL-specification injector and a needle head with the specification of 20G to extract the spinning solution obtained in the step (2), fixing the spinning solution on an electrostatic spinning device, carrying out electrospinning under the voltage of 15kV, the receiving distance of 10cm and the jet flow speed of 0.5mL/h to obtain a nanofiber antibacterial film;
(4) And putting the collected film into a vacuum drier for drying for 24h for later use.
Example 2
A method for preparing a cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning comprises the following steps:
(1) Preparing a cyclodextrin curcumin clathrate compound: adding deionized water into 2-hydroxypropyl-beta-cyclodextrin, stirring to obtain paste, adding curcumin with the amount of 1/2 of cyclodextrin substance, grinding at room temperature for 2 hours, adding a small amount of deionized water, filtering, and freeze-drying the filtrate;
(2) Preparing a spinning solution: dissolving the inclusion compound in the step (1) in 5mL of deionized water, standing for 4h, and preparing into spinning solution with the concentration of 180% (w/v);
(3) Extracting the spinning solution obtained in the step (2) by using a 5 mL-specification injector and a needle head with the specification of 19G, fixing the spinning solution on an electrostatic spinning device, carrying out electrospinning under the voltage of 15kV, the receiving distance of 18cm and the jet flow speed of 0.4mL/h to obtain a nanofiber antibacterial film;
(4) And putting the collected film into a vacuum drier for drying for 24h for later use.
FIG. 1 is an infrared spectrum of a cyclodextrin curcumin inclusion compound prepared in example 2; fig. 2 is an X-ray diffraction pattern of the cyclodextrin curcumin inclusion complex prepared in example 2; fig. 3 is a differential scanning calorimetry plot of the cyclodextrin curcumin inclusion prepared in example 2; the characteristic peak of CUR in FIG. 1 includes 3509.385cm due to stretching vibration of hydroxyl group -1 Absorption peak, 1628.135 cm generated by C = C expansion and contraction vibration -1 Has an absorption peak of 1602.582 cm -1 Stretching vibration of 1509.05 cm belonging to benzene ring skeleton -1 Corresponds to bending vibration of C = O, 962.3207cm -1 C = O peak of stretching vibration 855.7712 cm -1 And is the peak of the out-of-plane bending vibration of C-H.
The characteristic peak of 2-HP-beta-CD comprises 2924.086cm -1 Is CH 3 Expansion vibration of 1631.51 cm -1 、1401.536 cm -1 The peak at corresponds to C-H 2 1158.063 cm for telescopic vibration absorption -1 、1080.441 cm -1 、1027.408 cm -1 Is a C-O stretching vibration absorption peak.
In the physical mixture of 2-HP-beta-CD and CUR, the characteristic peaks of 2-HP-beta-CD and CUR are simultaneously appeared, and the characteristic peak of the CUR is 1628.135 cm -1 、1602.582 cm -1 、1510.014 cm -1 And 856.2534 cm -1 . The characteristic peak of the 2-HP-beta-CD appears to be 1401.536 cm -1 、1154.688 cm -1 、1082.37 cm -1 、1027.408 cm -1 。
In the inclusion compound, the peak of CUR completely disappears and is covered by 2-HP-beta-CD, so that the spectrum of the inclusion compound is very similar to the infrared spectrum of 2-HP-beta-CD, which indicates that the CUR and the 2-HP-beta-CD are successfully included in the inclusion compound.
In figure 2, CUR is crystal powder, a plurality of sharp crystal diffraction peaks appear in an XRD diffraction pattern, 2-HP-beta-CD is amorphous powder, no crystal diffraction peaks exist in the pattern, the pattern of the mixture can be seen from the simple superposition of the patterns of HP-beta-CD and CUR, the crystal diffraction peak of CUR appears on the basis of the pattern of 2-HP-beta-CD, in the pattern of the inclusion compound, the crystal diffraction peak generated by CUR completely disappears, the pattern is almost the same as the pattern of HP-beta-CD, and the situation that the amorphous state is formed after the CUR molecules are included by the HP-beta-CD is shown, so that the crystal diffraction peak does not appear any more.
In fig. 3, CUR has a sharp endothermic peak at around 176 °, corresponding to the melting point of curcumin, and in the physical mixture of β -CD and CUR, the peak generated by curcumin is slightly shifted and the intensity is significantly reduced, probably due to the inclusion reaction of a part of curcumin and cyclodextrin during the heating of the physical mixture. In the inclusion compound, the peak of CUR completely disappears, thus proving that a new substance is formed, namely, the inclusion of the inclusion compound is successful.
Comparative example 1
For comparison, a spinning solution was prepared directly on the basis of example 2, and the specific operations were as follows:
(1) Preparing a spinning solution: adding cyclodextrin and curcumin with the mass ratio of 2;
(2) Extracting the spinning solution obtained in the step (2) by using a 5 mL-specification injector with a needle head specification of 19G, fixing the spinning solution on an electrostatic spinning device, carrying out electrospinning at a voltage of 15kV, a receiving distance of 18cm and a jet flow speed of 0.4mL/h to obtain a nanofiber antibacterial film;
(3) And putting the collected film into a vacuum drier for drying for 24h for later use.
In the antibacterial experiment, the diameter of a glass culture dish is 100mm, the culture dish is prepared with a soybean agar culture medium, the culture medium is uniformly coated with a staphylococcus aureus culture solution, two groups of 2-hydroxypropyl-beta-cyclodextrin curcumin inclusion compound electro-spinning films with the same mass are weighed (a sample in figure 4a is obtained by preparing the inclusion compound through grinding and electro-spinning, namely example 2, and a sample in figure 4b is obtained by directly preparing the electro-spinning solution and electro-spinning, namely comparative example 1), are trimmed and stacked into a square with the side length of 10mm, and the square is placed in the culture dish, so that the thickness of each part is not uniform due to stacking, the film is not uniformly diffused in the culture dish, as shown in figures 5a and 5b, the widest part 1 of the film in figure 5a is 22mm, the narrowest part 2 is 17mm, the widest part 1 of the film in figure 5b is 24mm, and the narrowest part 2 is 13mm after the film is diffused. After the membrane is cultured in a thermostat at 37 ℃ for 24 hours, as shown in fig. 6a and 6b, a dark transparent bacteriostatic ring is obviously formed around the cyclodextrin curcumin inclusion compound film, the average width of the bacteriostatic ring in fig. 6a and 6b is 2.5mm, and the culture medium outside the bacteriostatic ring is covered by staphylococcus aureus, so that the 2-hydroxypropyl-beta-cyclodextrin curcumin inclusion compound electrospun membrane has an inhibitory effect on staphylococcus aureus.
As shown in fig. 7, the electrospun film samples of comparative example 1 and example 2, which are weighed to be equal in mass, are respectively dissolved in water with equal amount, and it can be obviously observed that the upper layer of the solution of the comparative example 1 on the left side is suspended insoluble substances and is free curcumin; the right example 2 sample solution was completely dissolved and the solution was clear. Thus, an advantage of electrospinning with inclusion compounds in the examples is that there is no free curcumin in the film that is not included.
Comparative example 1 is compared with example 2, except that the two steps of preparing the cyclodextrin flavonoid inclusion compound and preparing the spinning solution in example 2 are simplified into one step. However, the comparative example 1 has the disadvantage that free curcumin exists on the nanofiber antibacterial film, the curcumin is insoluble and cannot be utilized by organisms, and the embodiment has no problem, namely, the embodiment 2 has better antibacterial effect on the premise of the same curcumin dosage.
The foregoing shows and describes the general principles and features of the present invention, together with the advantages thereof. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.

Claims (4)

1. A method for preparing cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning is characterized by comprising the following steps:
(1) Preparing a cyclodextrin flavonoid clathrate compound: adding deionized water into cyclodextrin by grinding method, stirring to obtain paste, adding flavonoids by times, grinding, adding small amount of deionized water, filtering to remove non-included flavonoids, and freeze drying the filtrate;
(2) Preparing a spinning solution: dissolving the cyclodextrin flavonoid inclusion compound obtained in the step (1) in deionized water to obtain a high-concentration spinning solution;
(3) Performing electrostatic spinning on the spinning solution obtained in the step (2) to obtain a nanofiber antibacterial film, and finally performing vacuum drying to obtain the nanofiber antibacterial film;
the mass ratio of the cyclodextrin to the flavonoid compound in the step (1) is 2;
the concentration of the high concentration spinning solution in said step (2) is 160% -200% w/v;
the cyclodextrin adopts 2-hydroxypropyl-beta-cyclodextrin, and the flavonoid compound adopts curcumin;
and (3) no polymer is added in the preparation of the spinning solution in the step (2).
2. The method for preparing the cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrospinning according to claim 1, wherein the method comprises the following steps: and (3) electrostatic spinning is carried out by adopting an injector with the specification of 5mL, a needle with the specification of 22G to 19G and the voltage of 15kV to 18kV, a receiving screen is grounded and received by adopting aluminum foil, the distance between the needle and the receiving screen is 10 to 18cm, the jet flow rate in the electrostatic spinning process is 0.3 to 1.0mL/h, and the ambient humidity is 25 to 50 percent.
3. The cyclodextrin flavonoid inclusion compound nano-antibacterial film prepared by the method of claim 1 or 2.
4. The application of the cyclodextrin flavonoid inclusion compound nano-antibacterial film according to claim 3 in preparing antibacterial drugs or dressings.
CN202110936479.XA 2021-08-16 2021-08-16 Method for preparing cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning and application Active CN113694042B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110936479.XA CN113694042B (en) 2021-08-16 2021-08-16 Method for preparing cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110936479.XA CN113694042B (en) 2021-08-16 2021-08-16 Method for preparing cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning and application

Publications (2)

Publication Number Publication Date
CN113694042A CN113694042A (en) 2021-11-26
CN113694042B true CN113694042B (en) 2022-10-14

Family

ID=78652770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110936479.XA Active CN113694042B (en) 2021-08-16 2021-08-16 Method for preparing cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning and application

Country Status (1)

Country Link
CN (1) CN113694042B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102851789A (en) * 2012-09-14 2013-01-02 东华大学 Preparation method of beta-cyclodextrin inclusion compound-containing electrospun fiber
CN105568552A (en) * 2016-01-14 2016-05-11 武汉轻工大学 Quercetin inclusion compound electrospining nanofilm and preparation method and application thereof
CN112831864A (en) * 2021-01-29 2021-05-25 东北农业大学 Perilla aldehyde nanofiber and preparation method and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102851789A (en) * 2012-09-14 2013-01-02 东华大学 Preparation method of beta-cyclodextrin inclusion compound-containing electrospun fiber
CN105568552A (en) * 2016-01-14 2016-05-11 武汉轻工大学 Quercetin inclusion compound electrospining nanofilm and preparation method and application thereof
CN112831864A (en) * 2021-01-29 2021-05-25 东北农业大学 Perilla aldehyde nanofiber and preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
静电纺丝技术包埋抗菌物质研究进展;于栋等;《食品工业科技》;20200115(第02期);364-370 *
静电纺丝载药纤维及其在经皮递药系统中的研究进展;叶佩雯等;《中国药学杂志》;20191222(第24期);39-47 *

Also Published As

Publication number Publication date
CN113694042A (en) 2021-11-26

Similar Documents

Publication Publication Date Title
Ali et al. Antibacterial bi-layered polyvinyl alcohol (PVA)-chitosan blend nanofibrous mat loaded with Azadirachta indica (neem) extract
Chen et al. Electrospun thymol-loaded porous cellulose acetate fibers with potential biomedical applications
Hadipour-Goudarzi et al. Electrospinning of chitosan/sericin/PVA nanofibers incorporated with in situ synthesis of nano silver
Cremar et al. Development of antimicrobial chitosan based nanofiber dressings for wound healing applications
CN102584211B (en) Method for preparing micro/nano porous ceramic fibers by low-temperature electrostatic spinning
CN103394114B (en) A kind of preparation method of medical dressing chitosan-based superfine fiber carrier material
CN110144124B (en) Composite material of quaternized chitin and silk fibroin and preparation and application thereof
CN104383606B (en) A kind of high-strength high-elasticity intravascular stent and preparation method thereof
CN102493126A (en) Composite fiber material containing nanosilver and preparation method thereof
Pathalamuthu et al. Enhanced performance of Aloe vera incorporated chitosan-polyethylene oxide electrospun wound scaffold produced using novel Spirograph based collector assembly
Ali et al. Polyvinyl alcohol (PVA)–Azadirachta indica (Neem) nanofibrous mat for biomedical application: formation and characterization
CN105525441A (en) Foldable multilayer cross-linked composite fiber net film as well as preparation method and application thereof
CN110292652B (en) Mercaptobenzeneboronic acid activated gold nanoparticles as well as preparation method and application thereof
Zhang et al. Fabrication of green poly (vinyl alcohol) nanofibers using natural deep eutectic solvent for fast-dissolving drug delivery
Li et al. Functional nanofibrous biomaterials of tailored structures for drug delivery—a critical review
Raza et al. Recent developments in polysaccharide-based electrospun nanofibers for environmental applications
Li et al. Preparation and characterization of electrospun PLA/PU bilayer nanofibrous membranes for controlled drug release applications
CN1837435B (en) Composite nano-grade silk fiber product and method for preparing the same
Nadem et al. Cross-linked poly (vinyl alcohol) nanofibers as drug carrier of clindamycin
CN116672485A (en) Preparation method of multifunctional nanofiber membrane for promoting skin wound healing
CN1793445A (en) Organic hollow superfine fibre composition and preparation and application thereof
CN103451849A (en) Nano-silver-containing polybutylene succinate nanofiber membrane and preparation method and application thereof
Alam et al. Collagen/Nigella sativa/chitosan inscribed electrospun hybrid bio-nanocomposites for skin tissue engineering
Khan et al. Regeneration and modification of cellulose acetate from cigarette waste: Biomedical potential by encapsulation of tetracycline hydrochloride
CN113694042B (en) Method for preparing cyclodextrin flavonoid inclusion compound nano antibacterial film by polymer-free electrostatic spinning and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant